Rev. OFIL 2017, 27;4:335-340
Fecha de recepción: 03/10/2016 – Fecha de aceptación: 28/02/2017
Alonso Domínguez MT, Nájera Pérez MD, Soria Soto M, Titos Arcos JC, León Villar J, Sánchez Catalicio MM
Servicio de Farmacia. Hospital Universitario Morales Meseguer. Murcia (España)
____
Correspondencia:
Mª Teresa Alonso Domínguez
Servicio de Farmacia
Hospital Universitario Morales Meseguer
Avda. Marqués de los Vélez, s/n
30008 Murcia
Correo electrónico: Teresaldo87@gmail.com
____
SUMMARY
Purpose: To analyze the effectiviness and safety of regorafenib in patients diagnosed with metastatic colorectal cancer in a hospital clinical practice
Material and methods: An 18 months observational retrospective study that included patients on regorafenib. The following variables were included: gender, age, ECOG (Eastern Cooperative Oncology Group) scale, initial dose and adjustments, KRAS gene (mutated or native), previous line treatment and adverse events (AEs). In terms of effectiveness: Overall survival (OS), progression-free survival (PFS), response to treatment according to RECIST (Response Evaluation Criteria in Solid Tumors), duration of therapy and reason for discontinuation.
Results: A total of 33 patients with a median of 60 years old (36-79), started the treatment; 17 (51.5%) were male and a median duration of treatment of 3.3 months (0.4-17.3). 72.7% (24) had an ECOG 0-1. 57.5% (19) had mutated K-RAS and a median of 3 (1-5) previous line treatments. 84.4% of patients began with a full dose (160 mg) and 33.3% (11) had dose adjustment. The median days of treatment was 3.3 (0.4-17.3); SLP 3.8 (0.4-17.3) and the OS was 4.6 months (0.4-11.4). 84.8% (28) of patients reported adverse events. The response was evaluated in 87.8% (29) of the patients and 72.4% (21) had disease progression (DP).
Key Words: Regorafenib, metastatic colorectal cancer, effectiveness, safety.
____
Download PDF: Evaluación de la efectividad y seguridad de regorafenib en la práctica clínica habitual